Characterizing withdrawal from long-acting injectable buprenorphine: An observational case series
Participants (last dose of Buvidal® 64 mg Monthly) experienced minimal or mild withdrawal signs and symptoms, usually peaking in severity between 5 and 8 weeks after the last dose. These results are encouraging, however clinical trials comparing withdrawal outcomes between LAIB, sublingual buprenorphine (SL BPN) and methadone are required to inform treatment planning.
Authors
- Llewellyn Mills (ORCID: https://orcid.org/0000-0002-5320-087X)
- Victoria Hayes
- Gaye Byron
- Emma Black (ORCID: https://orcid.org/0000-0002-3936-2434)
- Nicholas Lintzeris (ORCID: https://orcid.org/0000-0001-5229-8257)
- Andrew A. Somogyi (ORCID: https://orcid.org/0000-0003-4779-0380)
- Benjamin T. Trevitt (ORCID: https://orcid.org/0009-0004-4528-4235)
- Arshman Sahid
- Carolyn Stubley
Institutions
- The University of Sydney (AU)
- Royal Brisbane and Women's Hospital (AU)
- South Eastern Sydney Local Health District (AU)
- The University of Adelaide (AU)
Publication Details
- Journal
- Drug and Alcohol Dependence Reports
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1016/j.dadr.2025.100329
- Citations
- 3
- Primary Topic
- Opioid Use Disorder Treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.64